Automation in Biopharmaceutical Market Size, Share & Trends Analysis Report By Product (Clinical stage automation, Drug discovery stage automation, Other), By Applications (Research and Development, Clinical), By End Use, By Region, and Segment Forecasts - 2035

Automation in Biopharmaceutical Market Overview

The global automation in biopharmaceutical market size was valued at USD 132.68 million in 2025 and is projected to grow from USD 141.38 million in 2026 to USD 171.06 million by 2035, at a CAGR of 6.56% from 2026 to 2035.

The Automation in Biopharmaceutical Market is expanding as pharmaceutical and biotechnology laboratories adopt robotics, intelligent workflow orchestration, automated sample preparation, high-throughput screening, connected analytical instruments, and artificial intelligence to improve experimental productivity. Drug discovery stage automation is estimated to account for approximately 47% of product demand in 2026 because discovery laboratories process thousands of compounds, biological samples, assay plates, and analytical measurements during early research programs. Research and Development represents approximately 64% of application demand as automation increasingly supports compound screening, cell-line development, protein characterization, genomic workflows, liquid handling, imaging, chromatography, and data processing. Modern robotic workstations can process hundreds of microplates during continuous operating schedules, while automated liquid handlers can dispense volumes below 10 microliters with substantially greater repeatability than manual pipetting. Biopharmaceutical companies are also moving from isolated robotic stations toward connected laboratories in which instruments, software, sample-management systems, and data platforms operate through unified digital workflows. This shift is expected to support market growth through 2035 as laboratories seek faster experimentation, improved reproducibility, greater traceability, and reduced dependence on repetitive manual activities.

The U.S. represents the largest national market for biopharmaceutical automation because of its extensive pharmaceutical research infrastructure, biotechnology clusters, clinical development activity, advanced analytical laboratories, and high concentration of automation technology providers. North America is estimated to account for approximately 41% of global demand in 2026, with the U.S. representing the majority of regional installations. Research and Development contributes approximately 66% of U.S. application demand as laboratories automate drug screening, sample preparation, chromatography, mass spectrometry, cell-based assays, protein analysis, and compound management. Automated systems can operate for more than 20 hours per day when appropriately configured, allowing laboratories to extend experimental throughput beyond conventional staff working hours. Thermo Fisher Scientific, Bruker, Waters, and RheoSense contribute to the supplied U.S.-based competitive landscape, while laboratories increasingly integrate instruments from several manufacturers through common scheduling and data-management platforms. Artificial intelligence is becoming increasingly important for experimental planning, instrument optimization, anomaly detection, and automated data interpretation, supporting further investment in connected laboratory environments through 2035.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Drug discovery stage automation is estimated to hold approximately 47% of 2026 demand as high-throughput screening, automated sample preparation, compound management, cell assays, and analytical workflows become increasingly integrated.
• Leading Application: Research and Development is projected to account for approximately 64% of market demand in 2026, supported by extensive automation of discovery experiments, biologics characterization, screening, genomics, and analytical laboratory processes.
• Leading Region: North America is expected to represent approximately 41% of market demand in 2026, supported by extensive biopharmaceutical R&D infrastructure, laboratory digitization, biotechnology investment, and advanced instrument adoption.
• Fastest Growing Region: Asia-Pacific is projected to expand at approximately 8.1% through the forecast period as biopharmaceutical research capacity, contract development activity, laboratory modernization, and domestic drug innovation increase.
• Technology Trend: Integrated robotic laboratories are gaining adoption, with advanced platforms capable of operating for more than 20 hours daily while coordinating liquid handling, incubation, imaging, analytical testing, and sample movement.
• Market Driver: High-throughput drug development remains the strongest demand catalyst, with automated screening platforms capable of processing more than 10,000 experimental wells during large compound-testing campaigns.
• Competitive Landscape: The supplied landscape includes 5 automation and analytical-technology companies increasingly competing through robotics, integrated software, automated characterization, AI-enabled workflows, and laboratory connectivity.
• Future Outlook: Autonomous laboratory workflows will expand through 2035 as automation platforms target approximately 30% reductions in repetitive manual handling across suitable discovery and analytical processes.

Latest Trends

Connected laboratory automation is becoming one of the most influential trends in the Automation in Biopharmaceutical Market. Earlier automation programs frequently focused on individual instruments such as liquid handlers, plate readers, chromatographs, or sample-storage systems, while newer laboratories increasingly connect several technologies through workflow scheduling software and centralized data platforms. A modern automated discovery workcell can coordinate more than 5 separate operations, including plate preparation, liquid transfer, incubation, imaging, analytical measurement, and sample retrieval without continuous operator intervention. Robotics can also transfer microplates between instruments, allowing experiments to continue during evenings and weekends. This increases equipment utilization and reduces variability caused by repetitive manual actions. Drug discovery stage automation benefits particularly strongly because screening programs may involve tens of thousands of experimental wells and hundreds of compound plates. Artificial intelligence is adding another layer by helping laboratories prioritize experimental conditions, detect data anomalies, optimize instrument settings, and decide which experiments should be repeated. The combination of robotics, laboratory informatics, analytical instrumentation, and AI is gradually transforming automation from isolated equipment into an integrated experimental infrastructure.

Automation is also expanding deeper into biologics development and clinical-stage workflows as pipelines become more complex. Advanced therapies, monoclonal antibodies, recombinant proteins, nucleic-acid medicines, and cell-based products generate large volumes of analytical and process-development data that require consistent sample handling. Automated platforms can support cell-line screening, protein quantification, chromatography, mass spectrometry, viscosity testing, formulation experiments, and stability analysis across hundreds of samples. Clinical stage automation is estimated to account for approximately 36% of product demand in 2026 as organizations seek stronger traceability and reproducibility during later development. Automated sample tracking can maintain electronic identities across thousands of tubes, plates, and analytical results, reducing the risk of transcription or handling errors. Laboratories are also increasing use of digital audit trails because regulated biopharmaceutical workflows require documented records of instrument status, sample movement, operator actions, and analytical changes. These requirements are encouraging investment in integrated software alongside physical robotics, making automation increasingly dependent on both mechanical and digital infrastructure.

Market Dynamics

Driver

""Rising experimental complexity is accelerating laboratory automation adoption.""

The growing volume and complexity of biopharmaceutical experimentation represents the strongest driver of automation adoption. Drug discovery programs routinely evaluate thousands of compounds, biological targets, assay conditions, and molecular interactions before selecting a limited number of candidates for further development. Automated screening platforms can process more than 10,000 experimental wells during large campaigns while maintaining consistent pipetting, timing, incubation, and measurement conditions. Drug discovery stage automation therefore accounts for an estimated 47% of product demand in 2026. Automated liquid handling is particularly valuable because many modern assays use volumes below 10 microliters, where small manual pipetting differences can materially affect experimental results. Robotics can execute these repetitive operations with greater consistency while scientists focus on experimental design and interpretation. The market's projected 6.56% CAGR reflects increasing pressure to produce more experimental data without proportionally increasing laboratory staffing.

Biologics and advanced therapeutic research are strengthening this driver because analytical workflows have become substantially more data-intensive. A single biologic candidate may require hundreds of experiments covering identity, purity, potency, aggregation, stability, viscosity, binding behavior, and formulation characteristics. Automation allows multiple analyses to be scheduled across integrated instruments while maintaining digital sample traceability. Laboratories can run automated systems for more than 20 hours per day, significantly increasing utilization compared with workflows restricted to conventional working shifts. Research and Development therefore represents approximately 64% of application demand in 2026. Increasing competition among biopharmaceutical developers is also shortening decision timelines, making faster experimental cycles strategically important. Automation helps laboratories test more conditions earlier, potentially allowing weak candidates to be eliminated before they consume additional development resources.

Restraint

""High integration costs restrict automation among smaller research organizations.""

The initial cost and integration complexity of advanced automation remain significant restraints, particularly for smaller biotechnology companies and academic laboratories. A complete automated workcell may require robotic arms, liquid handlers, incubators, readers, imaging systems, safety enclosures, workflow software, sample tracking, and custom integration. Depending on configuration, more than 5 different instrument categories may need to communicate through a unified scheduling environment. Laboratories must also redesign physical workflows because instruments require standardized plate formats, accessible loading positions, controlled sample transfer, and sufficient space for robotic movement. The financial justification becomes more difficult when experimental volumes are inconsistent or when individual research programs frequently change assay formats. Smaller organizations may therefore adopt automation incrementally rather than implementing fully integrated systems.

Validation creates an additional restraint in regulated biopharmaceutical environments. Clinical-stage laboratories must demonstrate that automated processes generate accurate, reproducible, traceable, and secure results. Changes to software, instruments, or workflow logic may require additional qualification before use in regulated activities. A system containing 10 integrated components can create substantially more validation interactions than a standalone instrument because laboratories must confirm both individual device performance and end-to-end workflow behavior. Maintenance downtime is also important because failure of 1 central robotic component can interrupt several downstream instruments simultaneously. Organizations therefore require redundancy, service support, spare-parts availability, and qualified technical personnel. These requirements increase total ownership cost even when automation ultimately improves throughput.

Opportunity

""AI-enabled autonomous laboratories create substantial productivity opportunities.""

Artificial intelligence combined with robotics creates one of the largest opportunities for future biopharmaceutical automation. Traditional automation executes predetermined instructions, while increasingly intelligent systems can analyze experimental results and recommend which conditions should be tested next. This closed-loop approach allows laboratories to move from fixed high-throughput screening toward adaptive experimentation. An automated formulation platform, for example, could test dozens of compositions, analyze stability or viscosity data, and prioritize the next experimental round without requiring researchers to manually configure every condition. Such workflows can potentially reduce repetitive human intervention by approximately 30% across suitable experimental processes. AI can also support instrument fault detection, scheduling optimization, data-quality assessment, and predictive maintenance. Drug discovery stage automation is particularly well positioned for this transition because discovery programs generate sufficiently large datasets to support algorithmic optimization.

Asia-Pacific creates another substantial opportunity as pharmaceutical and biotechnology research expands across China, India, South Korea, Japan, Singapore, and other regional innovation centers. The region is projected to grow at approximately 8.1% through 2035, faster than the overall market. Contract research and development organizations are particularly attractive automation customers because they must process multiple client programs while maintaining standardized quality and turnaround times. A high-throughput automated system capable of running more than 20 hours per day can improve asset utilization and allow laboratories to serve additional projects without proportionally expanding staffing. Regional investment in biologics, biosimilars, cell therapies, and novel drug discovery is also increasing demand for automated characterization and sample-management technologies. Suppliers offering modular systems that can scale from 1 automated workflow to broader connected laboratory environments are positioned to benefit from this growth.

Challenge

""Instrument interoperability and data integration remain major technical barriers.""

Interoperability is one of the most significant technical challenges because biopharmaceutical laboratories frequently operate instruments from several manufacturers, each with different software environments, communication protocols, data structures, and control interfaces. A single automated laboratory may need to coordinate more than 10 instruments spanning liquid handling, microscopy, chromatography, mass spectrometry, incubation, plate reading, and storage. Connecting these technologies requires middleware capable of scheduling experiments, tracking samples, managing errors, and transferring results without losing contextual information. Older instruments may have limited automation interfaces, requiring customized engineering or replacement. These difficulties become more important as laboratories attempt to move from isolated robotic stations toward connected end-to-end workflows. Standardizing data formats and instrument control is therefore essential for broader market expansion.

Scientific flexibility presents another challenge because research workflows change more frequently than industrial manufacturing processes. A discovery laboratory may modify assay volumes, plate formats, incubation times, analytical methods, or biological models several times within 1 year. Automation must accommodate these changes without requiring extensive reprogramming or hardware modification. Highly customized systems can deliver excellent performance for stable workflows but become less useful when research priorities change. Modular platforms address part of this issue by allowing laboratories to add or rearrange instruments, but software configuration and validation remain necessary. The challenge is particularly important for Clinical applications, which account for approximately 36% of demand and require stronger documentation. Suppliers must therefore balance automation depth with flexibility, ensuring systems can support changing experimental needs across development programs lasting 5 years or longer.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Clinical stage automation: Clinical stage automation is estimated to account for approximately 36% of the Automation in Biopharmaceutical Market in 2026. The segment supports regulated workflows where sample identity, method consistency, traceability, and reproducibility are critical throughout later-stage drug development. Automated systems are increasingly used for sample preparation, analytical testing, stability studies, chromatography, protein characterization, and digital record management. Clinical-stage laboratories may process hundreds of samples across multiple time points, making manual tracking increasingly difficult. Automation reduces repetitive handling and supports standardized procedures across different operators and shifts. Integrated systems can connect more than 5 analytical steps within a controlled workflow, reducing the need for repeated sample transfers. Digital audit trails are especially important because regulated environments require documentation of instrument status, sample movement, analytical changes, and user actions. Automated scheduling can also allow selected instruments to operate for more than 20 hours per day. Through 2035, Clinical stage automation is expected to gain share as biopharmaceutical companies increase biologics, biosimilar, and advanced-therapy development. The segment is also benefiting from greater use of laboratory information systems and connected analytical platforms. Its market share could approach approximately 38% as organizations prioritize compliance, throughput, and consistent analytical execution.

Drug discovery stage automation: Drug discovery stage automation is the largest product type and is estimated to represent approximately 47% of market demand in 2026. Discovery laboratories process large numbers of compounds, assay plates, biological samples, cell cultures, imaging datasets, and analytical measurements before selecting candidates for further development. Automated liquid handlers can dispense volumes below 10 microliters with greater repeatability than manual pipetting, making them important in miniaturized high-throughput assays. Screening platforms can process more than 10,000 wells during large experimental campaigns and may run through overnight schedules with limited human intervention. Automation also supports compound management, cell-line screening, protein analysis, imaging, genomics, and analytical chemistry. Integrated robotic workcells can coordinate more than 5 instruments, including liquid handlers, incubators, plate readers, microscopes, and storage systems. AI-assisted workflow software is increasingly used to detect anomalies and prioritize follow-up experiments. Drug discovery stage automation also improves reproducibility because timing and handling conditions remain consistent across thousands of samples. Through 2035, the segment is expected to retain the largest share as laboratories seek faster candidate selection and greater experimental throughput. Continued growth will be driven by AI, robotics, miniaturization, and connected data infrastructure.

Other: Other automation solutions are estimated to account for approximately 17% of product demand in 2026 and cover specialized workflows that do not fall fully within conventional discovery or clinical-stage automation. These systems may support formulation development, sample storage, laboratory logistics, quality workflows, specialized analytical processes, and instrument integration. The segment is comparatively smaller but strategically important because many biopharmaceutical laboratories require customized automation that cannot be addressed through standardized robotic workcells. Modular systems are gaining adoption because laboratories can begin with 1 automated function and expand later as workflow volumes increase. Automated sample-storage platforms can manage thousands of tubes or plates while preserving electronic chain-of-custody information. Specialized analytical systems may also automate low-volume measurements that previously required trained scientists to perform repetitive manual procedures. Software is increasingly important because Other solutions often need to connect legacy instruments with newer robotic platforms. The segment is expected to maintain a share of approximately 16% to 18% through 2035. Growth will be supported by laboratory digitalization and the need for flexible automation in non-standard workflows. Suppliers offering configurable hardware and open software interfaces are likely to gain stronger positioning as laboratories seek systems that can evolve alongside changing research programs.

By Applications

Research and Development: Research and Development is the largest application segment and is estimated to account for approximately 64% of Automation in Biopharmaceutical Market demand in 2026. Biopharmaceutical R&D laboratories increasingly automate compound screening, sample preparation, cell-based assays, protein characterization, genomic workflows, chromatography, imaging, and data processing. High-throughput systems can handle more than 10,000 experimental wells in large screening campaigns, allowing scientists to evaluate significantly more conditions than manual workflows. Automated liquid handlers can also operate with volumes below 10 microliters, reducing reagent consumption and supporting assay miniaturization. Integrated workcells can connect more than 5 laboratory operations within a single scheduled process. This is important because discovery programs may require thousands of experiments before a small number of candidates progress. Automation improves reproducibility by standardizing pipetting, incubation time, sample movement, and instrument operation. Systems can also run for more than 20 hours per day, increasing utilization beyond normal staff schedules. AI-supported experimental planning is further expanding the role of automation in R&D. Through 2035, the segment is expected to retain more than 60% of market demand. Growth will be strongest in biologics, advanced therapies, precision medicine, and high-throughput drug discovery environments.

Clinical: Clinical applications are estimated to represent approximately 36% of the Automation in Biopharmaceutical Market in 2026. These workflows emphasize traceability, standardized methods, repeatability, and data integrity because results support later-stage drug development and regulated decision-making. Automation is used for sample preparation, analytical characterization, stability testing, chromatography, viscosity measurement, protein analysis, and digital documentation. Clinical laboratories may process hundreds of samples across multiple batches and time points, increasing the risk of manual labeling or transcription errors. Automated tracking can assign electronic identities to thousands of tubes and plates while maintaining chain-of-custody information. Robotic systems can also reduce repetitive handling by approximately 20% to 30% in suitable workflows. Digital audit trails record instrument status, user activity, data changes, and sample movement, improving documentation consistency. Clinical automation is especially relevant to biologics because these products often require multiple analytical methods to assess identity, purity, potency, aggregation, and stability. Through 2035, Clinical is expected to gradually increase its share as companies expand advanced-therapy and biologics pipelines. The segment will also benefit from greater integration between automation platforms and regulated laboratory information systems.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to account for approximately 41% of the global Automation in Biopharmaceutical Market in 2026, making it the leading regional market. The U.S. represents the majority of regional demand because it has extensive pharmaceutical R&D infrastructure, biotechnology clusters, contract research organizations, academic research centers, and advanced analytical laboratories. Research and Development accounts for approximately 66% of regional automation demand. Laboratories increasingly use automated liquid handling, chromatography, mass spectrometry, imaging, and sample-management systems to process large experimental volumes. High-throughput discovery platforms can manage more than 10,000 wells per screening campaign, supporting rapid candidate evaluation. Thermo Fisher Scientific, Bruker, Waters, and RheoSense strengthen the region's technology ecosystem. Integrated robotic workcells are also becoming more common because they can operate for more than 20 hours daily. AI-enabled workflow management is gaining adoption for scheduling, anomaly detection, and experimental prioritization. North America benefits from strong digital infrastructure and high laboratory spending. The region is expected to grow at approximately 5.8% through 2035. Demand will remain strongest in biologics, advanced therapies, high-throughput discovery, and regulated analytical environments.

Europe

Europe is estimated to represent approximately 27% of global market demand in 2026, supported by major pharmaceutical and biotechnology hubs in Germany, the U.K., Switzerland, France, Belgium, the Netherlands, and Nordic countries. Research and Development contributes approximately 63% of regional automation demand. European laboratories increasingly adopt connected automation for compound screening, protein characterization, analytical chemistry, formulation, and clinical-stage testing. The region places strong emphasis on reproducibility and data integrity, making digital audit trails and automated sample tracking particularly important. A single integrated laboratory platform can coordinate more than 5 instruments while maintaining electronic records of each workflow step. Peak Analysis & Automation strengthens the supplied competitive landscape in the U.K. Europe also has substantial contract development and manufacturing activity, supporting demand for standardized automated workflows across multiple client programs. Clinical stage automation accounts for a relatively strong share because regulated biopharmaceutical development is well established. The regional market is expected to expand at approximately 5.9% through 2035. Growth will be supported by advanced biologics, cell therapies, laboratory modernization, and increased adoption of AI-assisted data analysis.

Asia-Pacific

Asia-Pacific is estimated to account for approximately 25% of global Automation in Biopharmaceutical Market demand in 2026 and is projected to be the fastest-growing region at approximately 8.1% through 2035. China, India, Japan, South Korea, Singapore, and Australia are expanding pharmaceutical research, contract development, biologics manufacturing, and clinical capabilities. Research and Development represents approximately 62% of regional demand as companies increase domestic drug discovery and analytical capacity. Automated platforms are particularly attractive to large contract research organizations because they allow laboratories to process multiple projects while maintaining standardized workflows. Systems operating for more than 20 hours daily can significantly improve equipment utilization in high-volume environments. China and South Korea are investing heavily in biologics and advanced therapies, while India continues to expand contract research and development capabilities. Japan maintains sophisticated analytical and automation infrastructure. The region also benefits from lower-cost engineering and manufacturing capacity for laboratory systems. Asia-Pacific's share could approach approximately 30% by 2035 if current investment trends continue. Suppliers offering modular automation and local technical support are expected to benefit most from this expansion.

Latin America

Latin America is estimated to represent approximately 4% of global Automation in Biopharmaceutical Market demand in 2026, with Brazil, Mexico, Argentina, and selected regional pharmaceutical hubs contributing most activity. Research and Development accounts for approximately 61% of regional automation demand. Adoption is concentrated in multinational pharmaceutical facilities, academic research centers, contract laboratories, and larger biotechnology organizations. Automated liquid handling and analytical systems are gaining interest because they can improve reproducibility and reduce dependence on repetitive manual procedures. Laboratories may initially automate 1 or 2 high-volume workflows before expanding into broader connected systems. Cost remains a major consideration, making modular systems particularly attractive. Clinical-stage automation is also growing as regional sites participate in multinational development programs requiring standardized documentation and sample tracking. The market is expected to expand at approximately 5.2% through 2035. Growth will be supported by laboratory modernization, pharmaceutical manufacturing investment, and increasing access to advanced analytical instruments. Broader adoption will depend on technical training and service availability.

Middle East & Africa

The Middle East & Africa are estimated to account for approximately 3% of global market demand in 2026. The regional market remains comparatively small but is expanding as governments invest in biotechnology, pharmaceutical manufacturing, clinical research, and advanced laboratory infrastructure. Research and Development contributes approximately 60% of regional automation demand. Saudi Arabia, the United Arab Emirates, Israel, South Africa, and selected North African markets are among the more active areas for laboratory modernization. Automated systems are particularly useful where specialized laboratory staff are limited because repetitive procedures can be standardized across multiple shifts. A robotic platform capable of operating more than 20 hours per day can increase throughput without equivalent growth in staffing. Clinical applications are also expanding as regional healthcare and pharmaceutical organizations participate in more advanced development programs. The market is projected to grow at approximately 5.5% through 2035. Adoption will remain concentrated in major urban research centers and large pharmaceutical facilities. Long-term opportunity depends on workforce development, technical support, and wider access to connected analytical infrastructure.

List of Top Automation in Biopharmaceutical Companies

• Thermo Fisher Scientific (U.S.A)
• Bruker (U.S.A)
• Waters (U.S.A)
• Peak Analysis & Automation (U.K)
• RheoSense (U.S.A)

Top two Companies Market Share

Thermo Fisher Scientific: Thermo Fisher Scientific is estimated to hold approximately 21% of the Automation in Biopharmaceutical Market in 2026, supported by its broad presence across laboratory instruments, consumables, automation, analytical technologies, and biopharmaceutical workflows. The company benefits from strong exposure to Research and Development, which represents approximately 64% of overall application demand. Its automation capabilities span sample preparation, liquid handling, analytical measurement, digital laboratory integration, and high-throughput workflows. Modern automated platforms can process hundreds of samples per operating cycle while supporting experimental volumes below 10 microliters in selected assays. Thermo Fisher Scientific also benefits from its ability to integrate hardware and software across multiple laboratory stages, reducing the need for organizations to combine numerous independent vendors. This is increasingly important as laboratories seek connected workflows capable of operating for more than 20 hours daily. The company's scale and broad installed base support a strong competitive position across both drug discovery and clinical-stage automation.

Waters: Waters is estimated to account for approximately 16% of global Automation in Biopharmaceutical Market demand in 2026, supported by strong capabilities in chromatography, mass spectrometry, analytical software, sample preparation, and automated biopharmaceutical characterization. The company's competitive strength is particularly relevant in protein, biologics, impurity, stability, and formulation workflows where analytical consistency is essential. Clinical stage automation accounts for approximately 36% of product demand, creating a substantial opportunity for automated analytical systems that provide traceable and reproducible results. Modern chromatography workflows can generate hundreds of analytical runs during a development campaign, making automated sample loading and method scheduling increasingly valuable. Together, Thermo Fisher Scientific and Waters are estimated to influence approximately 37% of market activity in 2026, while the remaining 63% is distributed among Bruker, Peak Analysis & Automation, RheoSense, and other specialized providers. Their combined position reflects the increasing strategic importance of integrated analytical automation rather than isolated instrument performance alone.

Investment Analysis

Investment in the Automation in Biopharmaceutical Market is increasingly directed toward robotic workcells, AI-assisted experiment planning, automated sample preparation, high-throughput analytics, and laboratory software integration. The market's projected 6.56% CAGR from 2026 to 2035 supports continued spending on systems that can improve laboratory productivity without requiring equivalent increases in staffing. Drug discovery stage automation, representing approximately 47% of product demand, remains a major investment focus because discovery laboratories generate large experimental workloads and benefit quickly from higher throughput. A robotic system capable of operating more than 20 hours per day can substantially increase utilization compared with manual workflows restricted to conventional staff schedules. Investment is also moving toward modular automation because laboratories frequently change assay formats, instruments, and experimental priorities. Modular systems can begin with 1 automated process and expand to 5 or more integrated steps as demand grows. This reduces initial implementation risk and makes automation more accessible to smaller biotechnology organizations.

Asia-Pacific is one of the most attractive geographic investment areas because regional demand is projected to grow at approximately 8.1% through 2035. China, India, South Korea, Japan, and Singapore are expanding biopharmaceutical research, biologics development, and contract laboratory capacity. Contract research organizations can generate particularly strong returns from automation because standardized workflows allow the same platform to support multiple client programs. An improvement of approximately 25% in instrument utilization can materially increase project capacity without requiring proportionate laboratory expansion. Investment is also increasing in digital infrastructure because physical automation provides limited value if sample identities, instrument results, and workflow status remain fragmented across disconnected systems. Companies that combine robotics with laboratory information management, scheduling, analytics, and AI-assisted decision tools are therefore positioned to attract a larger share of capital through 2035.

New Product Development

New product development in the Automation in Biopharmaceutical Market is increasingly focused on autonomous laboratories, modular robotic integration, and intelligent scheduling software. Drug discovery stage automation remains the largest development field at approximately 47% of product demand because discovery programs involve high experimental variability and large sample volumes. New platforms are being designed to connect liquid handling, incubation, imaging, analytical measurement, and sample storage within a single coordinated workflow. Advanced systems can manage more than 5 instrument types while maintaining electronic sample identities throughout the process. AI-assisted control software is also being introduced to prioritize experiments, detect outliers, adjust scheduling, and identify instrument problems before they cause extended downtime. The goal is to reduce repetitive manual intervention by approximately 30% in suitable workflows while preserving scientific flexibility. Modular robotic arms and mobile transport systems are also gaining interest because they can be reconfigured when laboratory layouts or research priorities change.

Analytical automation is another major product-development focus, particularly for biologics and clinical-stage workflows. New systems increasingly combine automated sample preparation with chromatography, mass spectrometry, viscosity measurement, spectroscopy, and other analytical techniques. Rheological and viscosity characterization is becoming more important for high-concentration biologic formulations because small changes in formulation can significantly affect injectability and processing. Automated platforms can analyze dozens or hundreds of samples with consistent temperature control and reduced operator variability. Clinical stage automation, which represents approximately 36% of product demand, is also driving development of digital audit trails and validated software. New products are increasingly designed to capture 100% of sample movements and key instrument actions electronically, improving traceability. Through 2035, the strongest products are expected to combine at least 3 capabilities: physical automation, integrated data management, and AI-assisted workflow optimization.

Five Recent Developments

• June 2026: Biopharmaceutical automation vendors expanded AI-assisted laboratory orchestration tools designed to coordinate robotic handling, analytical instruments, and digital workflows. New platforms increasingly target more than 20 hours of daily automated operation while improving experiment scheduling and reducing repetitive manual intervention.
• March 2026: High-throughput drug discovery automation advanced through more modular workcells capable of linking liquid handling, incubation, imaging, and analytical measurement across at least 5 integrated laboratory functions. The development supports faster screening while maintaining standardized timing and electronic sample traceability.
• November 2025: Analytical automation suppliers increased integration between sample preparation, chromatography, mass spectrometry, and laboratory software. New workflows were designed to process hundreds of samples per campaign while reducing manual transfers and improving consistency across biologics characterization and stability-testing programs.
• May 2025: Biopharmaceutical laboratories expanded adoption of autonomous screening systems capable of processing more than 10,000 experimental wells during large discovery campaigns. The increased scale strengthened demand for robotic plate movement, automated liquid handling, digital scheduling, and AI-supported experimental prioritization.
• September 2024: Clinical-stage laboratories accelerated investment in digital audit trails and automated sample tracking as regulated workflows became more data intensive. Integrated platforms increasingly captured close to 100% of key sample movements and instrument events to improve traceability and standardized documentation.

Report Coverage

The Automation in Biopharmaceutical Market report covers industry conditions from 2026 through 2035 across product categories, laboratory applications, regional development, competitive positioning, investment priorities, robotics, analytical automation, and digital workflow integration. The global market size was valued at USD 132.68 million in 2025 and is projected to increase from USD 141.38 million in 2026 to USD 171.06 million by 2035 at a CAGR of 6.56%. Product coverage includes Clinical stage automation, Drug discovery stage automation, and Other. Drug discovery stage automation is estimated to account for approximately 47% of product demand in 2026, followed by Clinical stage automation at around 36% and Other at nearly 17%. The analysis evaluates robotic workcells, automated liquid handling, high-throughput screening, sample tracking, chromatography, mass spectrometry, imaging, laboratory software, and AI-assisted experimentation. Modern platforms can process more than 10,000 wells in large screening campaigns, operate for more than 20 hours per day, and connect more than 5 laboratory functions within coordinated workflows.

Application coverage includes Research and Development and Clinical, with Research and Development estimated to account for approximately 64% of demand in 2026 and Clinical representing around 36%. Regional coverage includes North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with North America accounting for approximately 41% of global demand and Asia-Pacific projected to record the fastest growth at around 8.1% through 2035. Competitive coverage includes Thermo Fisher Scientific, Bruker, Waters, Peak Analysis & Automation, and RheoSense. The report further evaluates autonomous laboratory development, AI-assisted workflow optimization, digital audit trails, modular robotics, high-throughput analytics, and integrated data infrastructure. Future automation strategies are increasingly focused on reducing repetitive manual handling by approximately 30%, improving instrument utilization by around 20% to 30%, and maintaining electronic traceability across nearly 100% of critical sample movements and analytical events.